Prosight Management, LP Cytom X Therapeutics, Inc. Transaction History
Prosight Management, LP
- $372 Million
- Q3 2024
A detailed history of Prosight Management, LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 3,022,109 shares of CTMX stock, worth $3.02 Million. This represents 0.96% of its overall portfolio holdings.
Number of Shares
3,022,109Holding current value
$3.02 Million% of portfolio
0.96%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
68Shares Held
50.4MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$7.81 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.23 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$5.16 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$4.81 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$3.1 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $66M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...